Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640612 | 0.87 | CA1 (0.45) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL19937711 | 0.82 | SMN1; SMN2 (0.38) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL20064076 | 0.79 | PSEN1 (0.47) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL12241503 | 0.79 | RAB9A (0.52) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL31051519 | 0.79 | CA1 (0.43) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL27100482 | 0.79 | CCNE1 (0.44) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL13266901 | 0.78 | CA1 (0.47) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL13039 | 0.78 | FPR3 (0.54) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL20877512 | 0.78 | CA1 (0.47) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL27819346 | 0.78 | CA1 (0.47) | CA1CA2CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| EP-2402327-A1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | Advinus Therapeutics Private Limited (IN) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011095997-A1 | BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095997-A1 | BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
| EP-1532111-B1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | GCK, GCKR, ALDOA | CA1 1550/4885CA2 381/4885CCNE2 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.